AR038839A1 - Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion - Google Patents
Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracionInfo
- Publication number
- AR038839A1 AR038839A1 ARP030100494A ARP030100494A AR038839A1 AR 038839 A1 AR038839 A1 AR 038839A1 AR P030100494 A ARP030100494 A AR P030100494A AR P030100494 A ARP030100494 A AR P030100494A AR 038839 A1 AR038839 A1 AR 038839A1
- Authority
- AR
- Argentina
- Prior art keywords
- atorvastatin
- magnesium
- sodium
- crushing
- particles
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 15
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 15
- 229960005370 atorvastatin Drugs 0.000 title abstract 15
- 238000000034 method Methods 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002245 particle Substances 0.000 abstract 8
- 239000011777 magnesium Substances 0.000 abstract 4
- 229910052749 magnesium Inorganic materials 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- -1 alkali metal salts Chemical class 0.000 abstract 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 2
- 239000000347 magnesium hydroxide Substances 0.000 abstract 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 2
- 239000000391 magnesium silicate Substances 0.000 abstract 2
- 229910052919 magnesium silicate Inorganic materials 0.000 abstract 2
- 235000019792 magnesium silicate Nutrition 0.000 abstract 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 abstract 2
- 208000030673 Homozygous familial hypercholesterolemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 239000004115 Sodium Silicate Substances 0.000 abstract 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 abstract 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 150000004645 aluminates Chemical class 0.000 abstract 1
- 229910052782 aluminium Inorganic materials 0.000 abstract 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
- ANBBXQWFNXMHLD-UHFFFAOYSA-N aluminum;sodium;oxygen(2-) Chemical compound [O-2].[O-2].[Na+].[Al+3] ANBBXQWFNXMHLD-UHFFFAOYSA-N 0.000 abstract 1
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract 1
- 239000000920 calcium hydroxide Substances 0.000 abstract 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract 1
- BWFCZHDTTAYGNN-CNZCJKERSA-N calcium;(3r,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound [Ca].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 BWFCZHDTTAYGNN-CNZCJKERSA-N 0.000 abstract 1
- 229910000397 disodium phosphate Inorganic materials 0.000 abstract 1
- 235000019800 disodium phosphate Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- 239000001095 magnesium carbonate Substances 0.000 abstract 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 abstract 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 abstract 1
- 235000019799 monosodium phosphate Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910001388 sodium aluminate Inorganic materials 0.000 abstract 1
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract 1
- 235000017550 sodium carbonate Nutrition 0.000 abstract 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 abstract 1
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 1
- 239000001488 sodium phosphate Substances 0.000 abstract 1
- 229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
- 235000011008 sodium phosphates Nutrition 0.000 abstract 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052911 sodium silicate Inorganic materials 0.000 abstract 1
- 235000019794 sodium silicate Nutrition 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una fórmula farmacéutica que tiene mejor biodisponibilidad y bioequivalencia e incluye partículas de atorvastatina amorfa y/o cristalina, cuyo tamano de partículas (d90) corresponde a menos de 150 mm, con tamano promedio de partículas (d50) de atorvastatina que oscila entre alrededor de 5 y 50 mm. La atorvastatina puede corresponder a una o más de las siguientes: atorvastatina de calcio, atorvastatina de magnesio, atorvastatina de aluminio, atorvastatina de hierro, y atorvastatina de zinc. Las fórmulas de atorvastatina pueden ser estabilizadas al mezclar la atorvastatina con un aditivo consistente en sales de un metal alcalino que corresponde entre alrededor del 1.2% y menos del 5% peso en agua de la fórmula. El aditivo consistente de sales de metales alcalinos puede corresponder a uno o más de los siguientes: carbonato de sodio, bicarbonato de sodio, hidróxido de sodio, silicato de sodio, ortofosfato de hidrógeno de disodio, fosfato de dihidrógeno de sodio, fosfato de hidrógeno de disodio, fosfato de sodio, aluminato de sodio, carbonato de calcio, hidróxido de calcio, carbonato de magnesio, hidróxido de magnesio, silicato de magnesio, aluminato de magnesio, e hidróxido de magnesio, silicato de magnesio, aluminato de magnesio, e hidróxido de magnesio aluminado. Las fórmulas de atorvastatina pueden utilizarse para el tratamiento de condiciones médicas que incluyen hipercolesterolemia primaria, disbetalpoproteinemia, e hipercolesterolemia familiar homocigota. Reivindicación 83: Un método para procesar la atorvastatina amorfa con el fin de disminuir el tamano de las partículas de atorvastatina amorfa, el método comprende la trituración de partículas de atorvastatina amorfa empleando para ello uno o varios de los siguientes métodos: trituración con chorro de aire, trituración con quebradora de bolas, trituración cad y multi-trituración a fin de reducir el tamano de las partículas de atorvastatina amorfa de tal manera que las partículas tengan un tamano (d90) inferior a 150 mm y alcancen un tamano de partícula promedio (d50) comprendido entre aproximadamente 5 y 50 mm.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN112DE2002 | 2002-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038839A1 true AR038839A1 (es) | 2005-01-26 |
Family
ID=27620520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100494A AR038839A1 (es) | 2002-02-14 | 2003-02-14 | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030175338A1 (es) |
| EP (1) | EP1336405A1 (es) |
| JP (1) | JP2005522444A (es) |
| KR (1) | KR20040101229A (es) |
| CN (1) | CN1642526A (es) |
| AP (1) | AP2004003112A0 (es) |
| AR (1) | AR038839A1 (es) |
| AU (1) | AU2003245736A1 (es) |
| BR (1) | BR0307720A (es) |
| CA (1) | CA2475722A1 (es) |
| CO (1) | CO5600997A2 (es) |
| EA (1) | EA200401059A1 (es) |
| EC (1) | ECSP045235A (es) |
| HR (1) | HRP20040829A2 (es) |
| IL (1) | IL163550A0 (es) |
| IS (1) | IS7404A (es) |
| MX (1) | MXPA04007905A (es) |
| NO (1) | NO20043790L (es) |
| OA (1) | OA12777A (es) |
| PE (1) | PE20030935A1 (es) |
| PL (1) | PL371337A1 (es) |
| WO (1) | WO2003068191A1 (es) |
| ZA (1) | ZA200406970B (es) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US7361772B2 (en) * | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| ATE452871T1 (de) | 2002-03-18 | 2010-01-15 | Biocon Ltd | Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| SI1631533T1 (sl) | 2003-04-22 | 2009-08-31 | Bicon Ltd | Nov postopek za stereoselektivno redukcijo beta - ketoestrov |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| EP1653930B1 (en) * | 2003-08-05 | 2007-12-19 | Zentiva, a.s. | Methods for the stabilization of atorvastatin |
| AU2003272080A1 (en) | 2003-09-18 | 2005-04-06 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| AU2005271407A1 (en) * | 2004-08-06 | 2006-02-16 | Transform Pharmaceuticals, Inc. | Novel fenofibrate formulations and related methods of treatment |
| US20090042979A1 (en) * | 2004-08-06 | 2009-02-12 | Transform Pharmaceuticals Inc. | Novel Statin Pharmaceutical Compositions and Related Methods of Treatment |
| JP2008509154A (ja) * | 2004-08-06 | 2008-03-27 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なスタチン薬剤組成物および関連治療方法 |
| JP2008514722A (ja) * | 2004-09-30 | 2008-05-08 | ドクター レディズ ラボラトリーズ リミテッド | 非結晶性アトルバスタチンカルシウム |
| AU2005298383A1 (en) * | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| EP1814541A4 (en) * | 2004-11-22 | 2009-10-28 | Dexcel Pharma Technologies Ltd | STABLE ATORVASTATIN FORMULATIONS |
| CA2589537A1 (en) * | 2004-12-02 | 2006-06-08 | Stephen Craig Dyar | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
| ES2263370B1 (es) * | 2005-02-16 | 2007-12-01 | Ercros Industrial, S.A. | Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion. |
| WO2006123358A2 (en) * | 2005-02-22 | 2006-11-23 | Sun Pharmaceutical Industries Limited | Stabilized atorvastatin-containing formulation |
| PT1879862E (pt) * | 2005-05-03 | 2011-04-19 | Ranbaxy Lab Ltd | Sais de magnésio de inibidores de hmg-coa-redutase |
| US20070004671A1 (en) * | 2005-05-20 | 2007-01-04 | Agarwal Sudeep K | Stable desloratadine compositions |
| WO2007004236A2 (en) * | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| CN101500555A (zh) * | 2005-08-04 | 2009-08-05 | 变换药品公司 | 包含非诺贝特和他汀的新型制剂及相关治疗方法 |
| WO2007053904A1 (en) | 2005-11-10 | 2007-05-18 | Alphapharm Pty Ltd | Process to control particle size |
| AU2006313009B2 (en) * | 2005-11-10 | 2013-10-24 | Alphapharm Pty Ltd | Process to control particle size |
| DE602006014193D1 (de) | 2005-11-21 | 2010-06-17 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure-magnesium |
| US20090111997A1 (en) * | 2005-11-23 | 2009-04-30 | Aaron Cote | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals |
| WO2007063551A1 (en) * | 2005-11-29 | 2007-06-07 | Biocon Limited | POLYMORPHS OF [R-(R*, R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(l-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-lH-PYRROLE-l-HEPTANOIC ACID MAGNESIUM SALT (2: 1) |
| EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| US20070202159A1 (en) * | 2006-02-02 | 2007-08-30 | Mathur Rajeev S | Pharmaceutical composition comprising stabilized statin particles |
| EP1818049A3 (en) * | 2006-02-10 | 2008-11-19 | LifeCycle Pharma A/S | Stabilized Atorvastatin |
| WO2007099552A2 (en) * | 2006-03-02 | 2007-09-07 | Matrix Labaratories Ltd | Novel crystalline form of atovastatin hemi-magnesium |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| SI22255A (sl) * | 2006-04-14 | 2007-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah |
| CN101516842A (zh) * | 2006-05-11 | 2009-08-26 | 百康有限公司 | 阿托伐他汀镁晶型b4及其方法 |
| US20080038332A1 (en) * | 2006-08-10 | 2008-02-14 | Cai Gu Huang | Stable pharmaceutical formulation comprising atorvastatin calcium |
| HU227610B1 (en) * | 2006-09-18 | 2011-09-28 | Richter Gedeon Nyrt | Pharmaceutical compositions containing rosuvastatin potassium |
| US20100029743A1 (en) * | 2006-09-27 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| CA2673418A1 (en) * | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical compound and composition |
| IS8587A (is) * | 2006-12-27 | 2008-06-28 | Actavis Group Hf. | Atorvastatin lyfjasamsetning |
| CN101224205B (zh) * | 2007-01-20 | 2010-11-17 | 石药集团中奇制药技术（石家庄）有限公司 | 一种阿托伐他汀和左旋氨氯地平的组合物及其制备方法 |
| IS8607A (is) * | 2007-02-09 | 2008-08-10 | Actavis Group Hf. | Stöðugar atorvastatin samsetningar |
| CZ300047B6 (cs) * | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
| BRPI0809849A2 (pt) * | 2007-04-13 | 2014-09-23 | Nicox Sa | Forma cristalina, processo para a preparação da forma cristalina, forma cristalina, e, composição. |
| US20110142883A1 (en) * | 2007-07-20 | 2011-06-16 | Actavis Group Ptc Ehf | Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| EP2285352A2 (en) * | 2008-05-13 | 2011-02-23 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
| WO2009138962A1 (en) * | 2008-05-15 | 2009-11-19 | Firmenich Sa | Delivery system for an active ingredient |
| EP2127628A1 (en) | 2008-05-27 | 2009-12-02 | Ranbaxy Laboratories Limited | Unit dose pack |
| CA2767560A1 (en) * | 2008-07-25 | 2010-01-28 | Alphapharm Pty Ltd | Atovaquone with a particle size diameter range (d90) of greater than 3um to about 10um |
| EP2341773A4 (en) * | 2008-09-24 | 2012-03-07 | Merck Sharp & Dohme | PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN |
| US20100151034A1 (en) * | 2008-09-30 | 2010-06-17 | Astellas Pharma Inc. | Granular pharmaceutical composition of atorvastatin for oral administration |
| CN101791297B (zh) * | 2010-02-10 | 2012-03-28 | 中国药科大学 | 阿托伐他汀钙口崩片及其制备方法 |
| WO2011121824A1 (ja) * | 2010-03-29 | 2011-10-06 | アステラス製薬株式会社 | 口腔内崩壊錠 |
| JP5614445B2 (ja) * | 2010-03-29 | 2014-10-29 | アステラス製薬株式会社 | 経口投与用粒子状医薬組成物 |
| US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| WO2011139256A2 (en) * | 2010-05-04 | 2011-11-10 | Bilgic Mahmut | Stable rosuvastatin formulations |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| WO2011154009A1 (en) * | 2010-06-10 | 2011-12-15 | Lifecycle Pharma A/S | Composition comprising an active principle in an amorphous form and a porous adsorbent material |
| US20120165386A1 (en) * | 2010-12-27 | 2012-06-28 | Ranbaxy Laboratories Limited | Stable oral pharmaceutial composition of atorvastatin |
| EP2779999A2 (en) | 2011-11-15 | 2014-09-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising atorvastatin and glimepiride |
| CN104069502B (zh) * | 2013-03-29 | 2018-02-16 | 北京罗诺强施医药技术研发中心有限公司 | 复合骨架材料及其药物组合物 |
| JP6507808B2 (ja) * | 2015-04-09 | 2019-05-08 | ニプロ株式会社 | 口腔内崩壊錠 |
| WO2017106130A1 (en) * | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Process for preparing pharmaceutical compositions |
| EP3184103A1 (en) | 2015-12-21 | 2017-06-28 | Hexal AG | Pharmaceutical composition comprising atorvastatin or a salt thereof |
| CN106420645A (zh) * | 2016-11-24 | 2017-02-22 | 浙江新东港药业股份有限公司 | 一种含阿托伐他汀钙片及制备方法 |
| CN108421045B (zh) * | 2018-04-02 | 2021-09-24 | 北京海晶生物医药科技有限公司 | 一种阿托伐他汀钙组合物、制剂及其制备方法 |
| CN109044989A (zh) * | 2018-10-09 | 2018-12-21 | 河南师范大学 | 一种阿托伐他汀钙胶囊制剂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| WO1994016693A1 (en) * | 1993-01-19 | 1994-08-04 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
-
2003
- 2003-02-14 EP EP03405088A patent/EP1336405A1/en not_active Withdrawn
- 2003-02-14 OA OA1200400219A patent/OA12777A/en unknown
- 2003-02-14 EA EA200401059A patent/EA200401059A1/ru unknown
- 2003-02-14 US US10/367,552 patent/US20030175338A1/en not_active Abandoned
- 2003-02-14 PL PL03371337A patent/PL371337A1/xx not_active Application Discontinuation
- 2003-02-14 AP APAP/P/2004/003112A patent/AP2004003112A0/en unknown
- 2003-02-14 JP JP2003567375A patent/JP2005522444A/ja active Pending
- 2003-02-14 KR KR10-2004-7012657A patent/KR20040101229A/ko not_active Application Discontinuation
- 2003-02-14 AU AU2003245736A patent/AU2003245736A1/en not_active Abandoned
- 2003-02-14 BR BR0307720-9A patent/BR0307720A/pt not_active IP Right Cessation
- 2003-02-14 WO PCT/IB2003/000505 patent/WO2003068191A1/en active Application Filing
- 2003-02-14 CN CNA038070286A patent/CN1642526A/zh active Pending
- 2003-02-14 CA CA002475722A patent/CA2475722A1/en not_active Abandoned
- 2003-02-14 PE PE2003000161A patent/PE20030935A1/es not_active Application Discontinuation
- 2003-02-14 MX MXPA04007905A patent/MXPA04007905A/es not_active Application Discontinuation
- 2003-02-14 IL IL16355003A patent/IL163550A0/xx unknown
- 2003-02-14 AR ARP030100494A patent/AR038839A1/es not_active Application Discontinuation
-
2004
- 2004-08-13 CO CO04079402A patent/CO5600997A2/es not_active Application Discontinuation
- 2004-08-13 IS IS7404A patent/IS7404A/is unknown
- 2004-08-16 EC EC2004005235A patent/ECSP045235A/es unknown
- 2004-09-01 ZA ZA200406970A patent/ZA200406970B/en unknown
- 2004-09-09 NO NO20043790A patent/NO20043790L/no unknown
- 2004-09-13 HR HR20040829A patent/HRP20040829A2/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IS7404A (is) | 2004-08-13 |
| ZA200406970B (en) | 2005-06-20 |
| IL163550A0 (en) | 2005-12-18 |
| PL371337A1 (en) | 2005-06-13 |
| CA2475722A1 (en) | 2003-08-21 |
| HRP20040829A2 (en) | 2006-07-31 |
| OA12777A (en) | 2006-07-06 |
| EP1336405A1 (en) | 2003-08-20 |
| NO20043790L (no) | 2004-11-08 |
| PE20030935A1 (es) | 2003-10-30 |
| AP2004003112A0 (en) | 2004-09-30 |
| ECSP045235A (es) | 2004-09-28 |
| US20030175338A1 (en) | 2003-09-18 |
| WO2003068191A1 (en) | 2003-08-21 |
| CO5600997A2 (es) | 2006-01-31 |
| EA200401059A1 (ru) | 2005-02-24 |
| BR0307720A (pt) | 2005-01-25 |
| AU2003245736A1 (en) | 2003-09-04 |
| MXPA04007905A (es) | 2004-11-26 |
| JP2005522444A (ja) | 2005-07-28 |
| KR20040101229A (ko) | 2004-12-02 |
| CN1642526A (zh) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038839A1 (es) | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion | |
| JP2005522444A5 (es) | ||
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| AR063471A1 (es) | Formulaciones para administracion parenteral de compuestos y sus usos | |
| IL174758A0 (en) | Solid-state montelukast | |
| MX2020008537A (es) | Sales, formas cristalinas y metodos de produccion de las mismas. | |
| MXPA05007909A (es) | Composiciones limpiadoras en la forma de una tableta. | |
| CO5200817A1 (es) | Procedimiento de preparacion de un acelerador para hormigon | |
| WO2007118159A3 (en) | Use of storage-stable aqueous solutions of chlorine dioxide to generate pure chlorine dioxide gas for decontamination | |
| ES2185412T3 (es) | Composiciones de celecoxib. | |
| MX2007003546A (es) | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. | |
| AR098773A1 (es) | Composiciones para cuidado oral que comprenden carbonato de calcio y arcilla | |
| RU2011117177A (ru) | ДОЗИРОВАННЫЕ ЛЕКАРСТВЕННЫЕ ФОРМЫ 3-(6-(1-(2,2-ДИФТОРБЕНЗО[d][1,3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ | |
| NZ606366A (en) | Stabilization of fsh | |
| AR098775A1 (es) | Composiciones para el cuidado oral que contienen carbonato de calcio y sílice | |
| AR095159A2 (es) | Una composición farmacéutica en forma de cápsula para administración oral | |
| BR112013006597A2 (pt) | tablete para desintegração oral em múltiplas camadas, e a fabricação do mesmo | |
| PE20040417A1 (es) | Forma de administracion de ibuprofeno sodico | |
| MX2009008870A (es) | Composiciones bucales de polifosfato. | |
| CO6460753A2 (es) | Procedimiento y composición para mejorar la absorción de agentes terapéuticos | |
| PH12020500389A1 (en) | Spherical silica for tubule occlusion | |
| CN102465050A (zh) | 耐硬水水溶性切削液 | |
| AR042630A1 (es) | Derivados de tetrahidroquinolina, composiciones farmaceuticas que los incluyen y su uso como medicamento. | |
| MX2021005119A (es) | Formulacion aerosolizada. | |
| AR055953A1 (es) | Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la producion de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |